Data-Driven Insights

Five Steps to a Better Specialty Pharmacy Data Contracting Strategy

December 10, 2018   |   Brandon Underwood

An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language, determine the metric outputs that are possible. This post looks at how the right specialty data contracting decisions enable diagnostic patient journey insights that help specialty brands save patient days of therapy.

Read More

Tags: , , , ,

Frequently Asked Questions – 340B Program

September 26, 2018   |   Brandon Underwood

The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is taken from the Q&A session of IntegriChain's recent 340B webinar. Topics discussed include growth in contract pharmacies/covered entities, 340B discount pricing for orphan drugs, and validation of 340B entities.

Read More

Tags: , , , , , , , , ,

Opioid Crisis Exposes Vulnerabilities in Suspicious Order Monitoring

August 20, 2018   |   Shivani Patel

The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny and need new approaches to monitor and report on irregular order patterns for controlled substances. This post discusses a new approach that provides visibility across pharmacy locations and wholesale distributors while weaving in additional demographic insights.

Read More

Tags: , , , , ,

3 Key Opportunities to Improve Specialty Patient Initiation

August 3, 2018   |   Sean McCarthy

Sean McCarthy

There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to First Fill and increase overall Fill Rate for new patient referrals. Each key opportunity to improve patient initiation is related to a friction point in the patient journey. In this post, IntegriChain Patient Access Segment Leader Sean McCarthy provides an overview of these key opportunities and the potential of analytics to unlock efficiencies for specialty brands.

Read More

Tags: , , , , , ,

The Economics of Rare Disease and Implications for Payer Contract Strategy

July 27, 2018   |   David Carlson

David Carlson

Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these products account for an ever increasing share of overall pharmaceutical sales. The Payer community is reaching for value as per patient costs rise. This post discusses value-based contracts as a mutually beneficial solution for Payers and pharmaceutical manufacturers and the meaningful role analytics can play in executing and managing these innovative agreements.

Read More

Tags: , , , , ,

Specialty Pharmacy Status/Sub-Status Analysis Highlights Inconsistencies in Data Quality

March 21, 2017   |   Brandon Underwood

Brandon Underwood offers a sneak peek at IntegriChain's upcoming Specialty Analytics benchmark report. IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory. Overall, IntegriChain and ProMetrics analyzed more than 657,000 sub-status records reported in Q4 2016. The brands we studied had comparable status/sub-status reporting requirements.

Read More

Tags: , , ,

Leveraging Scorecard Analytics to Optimize Changes to DSAs

June 2, 2016   |   Sunay Shah

In my last post, I explored how IntegriChain Scorecard Analytics can be used to validate whether the implementation of Distribution Service Agreements (DSAs) drives channel performance. In this post, we will deep dive with a step-by-step approach outlining how Scorecard Analytics can be leverage to optimize changes to DSAs. First, let’s look at the metrics. DSA metrics come in two basic flavors – performance and data transmission The performance metrics are typically composed of a service level metric, purchase stability (or demand variability) metric, and an inventory level metric. The data transmission metrics are typically composed of data delivery timeliness, completeness, and […]

Read More

Tags: , , ,

Trends in Specialty Pharmacy Channel Design – Takeaways from Asembia Specialty Pharmacy Summit

May 27, 2016   |   Colleen Hallett

The Asembia (formerly known as Armada) Specialty Pharmacy Summit is fast becoming the pharmaceutical industry’s most important meeting. This year’s Las Vegas show boasted a record attendance of nearly 5,000 pharmaceutical manufacturers, specialty pharmacies, payers, and solution vendors. As new therapies trend more and more towards high price, niche, or patient-tailored treatments often requiring special handling, this surge of interest in all things specialty pharmacy is no surprise. The enormous rise in specialty brand launches has changed the traditional channel distribution model. Life sciences distribution channels have become much more complicated, and this has led to an increase in the number […]

Read More

IntegriChain Continues to Lead in Automated, End-to-End Management of Pharma Distribution Service Agreements

April 6, 2016   |   Sunay Shah

Distribution Service Agreements (DSAs) have continued to evolve over recent years especially as they relate to how they evaluate channel performance. For the most part, manufacturers structure the agreements to ensure trade partners effectively and efficiently fulfill downstream orders, manage volatility of orders, maintain appropriate inventory level (as defined by manufacturer), and transmit data to manufacturers. As the industry matures in how DSAs are structured, we are seeing trends of new concepts such as misses being incorporated into agreements. However, what is very interesting is how much the industry has validated the efficacy of DSAs. Even as the agreements are […]

Read More

Tags: , , ,

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71